[Management of graft failure and erythroblastopenia in patients undergoing allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Date publication

novembre 2016

Journal

Bulletin du cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr POCHON Cécile

Tous les auteurs :
Cornillon J, Sicre de Fontbrune F, Chantepie S, Coiteux V, Gauthier J, Masouridi-Levrat S, Pochon C, Terriou L, Yakoub-Agha I, Dalle JH

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27810141

Résumé

Success of allogeneic hematopoietic stem cells transplantation requires both the underlying disease eradication and satisfying reconstitution of hematopoiesis from donor cells. However, reconstitution delays, secondary development or persistence of cytopenia are regularly observed and are potential causes of failure after allogeneic transplantation. These graft dysfunctions should be distinguished from non-engraftment/engraftment failure. Although these situations are relatively common, there is no consensus in the literature for their management. During the workshop of the SFGM-TC, the working group proposed recommendations from an analysis of the literature.

Mots clés

Allogreffe de cellules souches hématopoïétiques, Bone marrow transplantation, Dysfonction du greffon, Erythroblastopenia, Graft dysfunction, Érythroblastopénie

Référence

Bull Cancer. 2016 Nov;103(11S):S248-S254